High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3b(n)-IgG complexes

Blood

Volumn 88, Issue 1, 1996, Pages 184-193

  Lutz, Hans U ^a   Stammler, Pia ^b   Jelezarova, Emiliana ^b   Nater, Mena ^b   Späth, Peter J ^b  

^a ETH ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR I; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOSITIS; PRIORITY JOURNAL;

EID: 0029900936     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.1.184.184     Document Type: Article

References (35)

1. Ronda N, Hurez V, Kazatchkine MD: Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 64:65, 1993
2. Cometta A: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234, 1992
3. Kohsaka T, Abe J, Ashina T, Kobayashi N: Classical pathway complement activation in Kawasaki syndrome. J Allergy Clin Immunol 93:520, 1994
4. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341, 1986
5. Basta M, Kirshom P, Frank MM, Fries LF: Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 84:1974, 1989
6. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94:1729, 1994
7. Mollnes TE, Hogasen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M: Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding properties. Scand J Immunol 41:449, 1995
8. Duncan AR, Winter G: The binding site for C1q on IgG. Nature 332:738, 1988
9. Entwistle RA, Furcht LT: C1q component of complement binds to tibrinogen and fibrin. Biochemistry 27:507, 1988
10. Comis A, Easterbrook-Smith SB: Binding of complement component C1q by spectrin. Biochim Biophys Acta 870:426, 1986
11. Takata Y, Tamura N, Fujita T: Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates. J Immunol 132:2531, 1984
12. Yokoyama I, Waxman F: Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes. Immunology 80:168, 1993
13. Jacobs RJ, Reichlin M: Generation of low M.W., C3-bearing immunoglobulin in human serum. J Immunol 130:2775, 1983
14. Fries LF, Gaither TA, Hammer CH, Frank MM: C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 160:1640, 1984
15. Davis AE III, Harrison RA, Lachmann PJ: Physiologic inactivation of fluid phase C3b: Isolation and structural analysis of C3c, C3d,g (a2D), and C3g. J Immunol 132:1960, 1984
16. Gaither TA, Hammer CH, Frank MM: Studies of the molecular mechanisms of C3b inactivation and a simplified assay of β1H and the C3b inactivator (C3bINA). J Immunol 123:1195, 1979
17. Meri S, Pangburn MK: A mechanism of activation of the alternative complement pathway by classical pathway: Protection of C3b from inactivation by covalent attachment to C4b. Eur J Immunol 20:2555, 1990
18. Vyse TJ, Späth PJ, Davies KA, Morley BJ, Philippe P, Athanassiou P, Giles CM, Walport MJ: Hereditary complement factor I deficiency. Q J Med 87:385, 1994
19. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF: Large scale isolation of functionally active components of the human complement system. J Biol Chem 256:3995, 1980
20. Tack BF, Prahl JW: Third component of human complement: Purification from plasma and physicochemical characterization. Biochemistry 15:4513, 1976
21. Janatova J, Tack BF, Prahl JW: Third component of human complement: Structural requirements for its function. Biochemistry 19:4479, 1980
22. Lutz HU, Nater M, Stammler P: Naturally occurring antiband 3 antibodies have a unique affinity for C3. Immunology 80:191, 1993
23. Crossley LG: C3b inactivator and β1H. Methods Enzymol 80:112, 1981
24. Fasler S, Skvaril, Lutz HU: Electrophoretic properties of human IgG and its subclasses on sodium dodecyl-sulfate-polyacryl-amide gel electrophoresis and immunoblots. Anal Biochem 174:593, 1988
25. Fearon DT, Austen KF, Ruddy S: Properdin factor D: Characterization of its active site and isolation of the precursor form. J Exp Med 139:355, 1974
26. 3H-palmitoylated. J Biol Chem 268:12996, 1993
27. Schreiber RD, Pangburn MK, Lesavre PH, Müller-Eberhard HJ: Initiation of the alternative pathway of complement: Recognition of activators by bound C3b and assembly of entire pathway from six isolated proteins. Proc Natl Acad Sci USA 75:3948, 1978
28. Gadd KJ, Reid KBM: The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J 195:471, 1981
29. Sahu A, Pangburn MK: Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation. J Biol Chem 269:28997, 1994
30. Shohet JM, Beramaschini L, Davis AE, Carroll MC: Localization of the human complement component C3 binding site on the IgG heavy chain. J Biol Chem 266:18520, 1991
31. Lutz HU, Stammler P, Fasler S: Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. J Biol Chem 268:17418, 1993
32. Basta M, Fries LF, Frank MM: High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77:376, 1991
33. Basta M, Langlois PF, Marques M, Frank MM, Fries LF: High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74:326, 1989
34. Kulics J, Rajnavölgyi E, Füst G, Gergely J: Interaction of C3 and C3b with immunoglobulin G. Mol Immunol 20:805, 1983
35. Joiner KA, Fries LF, Schmetz MA, Frank MM: IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111. J Exp Med 162:877, 1985